The extinguished BEACON of bardoxolone: not a Monday morning quarterback story.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. Nrf2 Activation Does Not Protect from Aldosterone-Induced Kidney Damage in Mice.Antioxidants (Basel, Switzerland) · 2023
   Article
2. E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology.Journal of medicinal chemistry · 2023
   Review
3. Harnessing the Therapeutic Potential of the Nrf2/Bach1 Signaling Pathway in Parkinson's Disease.Antioxidants (Basel, Switzerland) · 2022
   Review
4. Oxidative Stress and NRF2/KEAP1/ARE Pathway in Diabetic Kidney Disease (DKD): New Perspectives.Biomolecules · 2022
   Review
5. Nrf2 Activation in Chronic Kidney Disease: Promises and Pitfalls.Antioxidants (Basel, Switzerland) · 2022
   Review
6. Continuous, Automated Breathing Rate and Body Motion Monitoring of Rats With Paraquat-Induced Progressive Lung Injury.Frontiers in physiology · 2020
   Article
7. Transcription Factors as Therapeutic Targets in Chronic Kidney Disease.Molecules (Basel, Switzerland) · 2018
   Review
8. N-acetyl-cysteine increases cellular dysfunction in progressive chronic kidney damage after acute kidney injury by dampening endogenous antioxidant responses.American journal of physiology. Renal physiology · 2018
   Article
9. Specialized Pro-resolving Lipid Mediators: Modulation of Diabetes-Associated Cardio-, Reno-, and Retino-Vascular Complications.Frontiers in pharmacology · 2018
   Review
10. The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases.Biophysical reviews · 2017
    Review
11. Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors.OncoTargets and therapy · 2017
    Article
12. Role of Nuclear Factor Erythroid 2-Related Factor 2 in Diabetic Nephropathy.Journal of diabetes research · 2017
    Review
13. Drug development: how academia, industry and authorities interact.Nature reviews. Nephrology · 2014
    Review
14. Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: biochemical, pharmacological and toxicological implications.Journal of proteomics · 2014
    Article
15. Chemical tuning enhances both potency toward nrf2 and in vitro therapeutic index of triterpenoids.Toxicological sciences : an official journal of the Society of Toxicology · 2014
    Article
16. Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.Drug design, development and therapy · 2014
    Review
17. Slowing progression of chronic kidney disease.Kidney international supplements · 2013
    Article
18. Diabetic nephropathy: diagnosis and treatment.Nature reviews. Endocrinology · 2013
    Review
19. The emerging role of the Nrf2-Keap1 signaling pathway in cancer.Genes & development · 2013
    Review

Corrections and comments

• Erratum issued

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as